BCL2 and B-cell chronic lymphocytic leukemia: The success of the BCL-2 inhibitor Venetoclax, in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and as a combinatorial therapy in acute myeloid leukemia [94–96], clearly demonstrates that the protein–protein interactions of BCL-2 family proteins are druggable.